Abstract: Described herein are compositions and methods targeting IL-3 signaling for reducing Alzheimer's disease (AD)-related pathology.

Abstract: This present invention provides a pharmaceutical composition comprising one or more ACAT inhibitors and one or more GLP-1RAs. It also provides a method for controlling body weight comprising co-administering to a subject in need one or more ACAT inhibitors and one or more GLP-1RAs.

Abstract: The present invention provides a method for treating and/or ameliorating a disorder of the lower urinary tract, comprising administering a composition comprising a glucagon like peptide 2 (GLP-2) receptor agonist to a patient in need thereof in an amount sufficient to treat and/or ameliorate the disorder of the lower urinary tract.

Abstract: The present invention provides methods for treating a condition or disorder that is associated with or mediated by dysregulation or dysfunction of the dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), e.g., microcephaly, autism spectrum disorder (ASD), or intellectual disability (ID). The methods of the invention involve administering to a subject in need of treatment a pharmaceutical composition that stimulates or upregulates a signaling cascade selected from BDNF-TrkB, mTOR, IGF-1 and ERK/MAPK signaling pathways.

Abstract: In a method for treating a cancer expressing secreted protein acidic and rich in cysteine (SPARC), a composition including an albumin and at least one cysteine bound thereto is administered to a subject in need thereof. The cancer expressing the SPARC may be at least one selected from the group consisting of a brain tumor, melanoma, breast cancer, rectal cancer and stomach cancer.

Abstract: Ovotransferrins with a degree of iron saturation from 0 to 15% are useful in the treatment of iron deficiency and iron deficiency anaemia, increasing the cell viability on gastric and intestinal cell models with respect to the holo-OvT 100%, when tested at the same concentrations, showing also a surprisingly better time dependent absorption of iron ions and a physiological trend allowing a single oral administration in 24 hours.

Abstract: The invention relates to a topical composition having a low anionic surfactant amount for use in the treatment and/or prevention of a corona virus infection.

Abstract: Disclosed is a serum albumin-thioredoxin fusion body which is improved in the activity thereof and is stable with respect to the activity. The serum albumin-thioredoxin fusion body is provided, which is characterized in that the thioredoxin is a modified from in which at least a cysteine residue located at position 73 from the N-terminal of an amino acid sequence for the thioredoxin or located at a position equivalent to the position 73 is substituted by another amino acid residue. the modified serum albumin-thioredoxin fusion body is superior in the activity and stability thereof, is reduced in immunogenicity and has superior safety compared with a fusion body in which the thioredoxin is non-modified form.

Abstract: The invention relates to the field of medicine, specifically to the field of treatment of conditions associated with Staphylococcus infection. The invention relates to a novel endolysin polypeptide specifically targeting a bacterial Staphylococcus cell. The invention further relates to said endolysin polypeptide for medical use, preferably for treating an individual suffering from a condition associated with Staphylococcus infection.

Abstract: Provided herein are compositions and methods related to compositions comprising an Ig protease fusion protein. Also provided herein are compositions and methods for therapeutic treatment, such as of autoimmune diseases, allergies, or other immunological disorders, or in combination with the administration of another therapeutic, with such Ig protease fusion protein.

Abstract: The present invention provides methods of treating cutaneous manifestations of psoriasis comprising topically applying to an affected skin area of a subject a pharmaceutical composition comprising a partially purified proteolytic enzyme mixture obtained from crude bromelain and a pharmaceutically acceptable carrier, thereby treating the cutaneous manifestations of psoriasis.

Abstract: There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises all or a portion of the following proteolipid protein (PLP) peptides: PLP 36-61: HE ALTGTEKLIET YF SKN YQD YEYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCA-DARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.

Abstract: An apparatus and method for determining administration form of a composition of an engineered virus-based nanoparticle for a treatment of an autoimmune condition are disclosed. The apparatus includes at least a processor and a memory communicatively connected to the at least a processor, wherein the memory contains instructions configuring the at least a processor to obtain administration data, wherein the administration data comprises a plurality of administrations of a composition of an engineered virus-based nanoparticle for a treatment of an autoimmune condition, compare the administration data and determine a critical administration as a function of the comparison.

Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.

Abstract: The invention relates to an autologous cancer vaccine and also to the method for producing same comprising the following steps: a) extracting the proteins contained in a serum or plasma sample obtained from a patient suffering from cancer; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or tricalcium phosphate.

Abstract: The present invention relates to animals and more specifically to insects. In more details the invention relates to an edible composition or insect artificial diet comprising bacteria, fungi or any fragment or spore thereof for use as a vaccine in preventing a microbial disease or infection in an insect. Still, the present invention relates to preventive methods and different uses relating to said compositions or bacteria, fungi or fragments or spores thereof.

Abstract: The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.

Abstract: The present invention relates to the field of immunogenic compositions and the use of such compositions in medicine. More particularly, it relates to immunogenic compositions comprising an immunogenic polypeptide from non-typeable Haemophilus influenzae, a PE-PilA fusion protein, and optionally an immunogenic polypeptide of UspA2 from Moraxella catarrhalis, for use in subjects having chronic obstructive pulmonary disease (COPD), in particular for reducing the frequency of severe exacerbations (i.e. severe AECOPDs).

Abstract: The present disclosure provides an N protein epitope mutation marker for preparing an epitope deletion-marked vaccine strain of type II porcine reproductive and respiratory syndrome virus (PRRSV) and use thereof, belonging to the technical field of biological products. In the mutation marker, one or more amino acids are mutated based on an epitope sequence at positions 92 to 103 of a C-terminal of an N protein of the type II PRRSV; and the epitope mutation marker has an amino acid sequence shown in SEQ ID NO: 1, where X1 is selected from the group consisting of T, P, and A; and X2 is selected from the group consisting of V and A.

Abstract: Provided herein are non-naturally occurring, broadly reactive, pan-epitopic antigens derived from Dengue virus that are immunogenic and elicit a broadly reactive immune response, such as a broadly reactive neutralizing antibody response, against Dengue virus subtypes following introduction into a subject. Also provided are non-naturally, broadly reactive occurring immunogens, immunogenic compositions, vaccines, subviral particles (SVPs), and virus-like particles (VLPs) comprising Dengue virus proteins or encoding polynucleotides. Methods of generating an immune response in a subject by administering the immunogens, vaccines, SVPs, VLPs, or immunogenic compositions thereof are provided. In particular, the immunogens comprise a Dengue virus protein, or an antibody binding portion thereof.

Abstract: The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

Abstract: The present disclosed and described technology are directed to multimodal mRNA-based immunotherapies that deliver both antigens and immunomodulators. Related formulations, method of administration, and kits are disclosed and described.

Abstract: Disclosed herein are nanoparticles comprising one or more Human papillomavirus (HPV) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a HPV infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

Abstract: The present disclosure generally relates to a personalized cancer vaccine having attenuated cancer cells transfected with at least one expression construct. The expression construct is capable of secretory expression of an antigenic polypeptide that could be derived from a protein from a virus. The personalized tumor vaccine, when administered to a subject in need thereof, is effective to activate an immune response.

Abstract: Provided is a vaccine composition for preventing respiratory syncytial virus (RSV) infection, which is in the form of a liposome formulation including a RSV antigen, monophosphoryl lipid A (MLA), and/or a cobalt-porphyrin-phospholipid (CoPoP) conjugate. The vaccine composition exhibits excellent vaccine efficacy from a RSV antigen with enhanced immunogenicity and a combination of immune adjuvants for enhancing immune activity and antigen presentation.

Abstract: Compositions and methods of inducing an immune response in a subject having RSV comprising administering a pharmaceutical composition comprising a prophylactic vaccine against RSV infection, wherein the vaccine comprises a live recombinant canine parainfluenza (CPI) vector backbone engineered to express a RSV F protein.

Abstract: There are provided herein, inter alia, complexes, compositions and methods for a vaccine for COVID-19. The cell-penetrating complexes provided herein may include a nucleic acid non-covalently bound to a cationic amphipathic polymer, the cationic amphipathic polymer including a pH-sensitive immolation domain. The cell-penetrating complexes provided herein are, inter alia, useful in vaccines, wherein the vaccine includes a ribonucleic acid including a sequence encoding a viral protein, a nucleic acid adjuvant and a cationic amphipathic polymer provided herein including embodiments thereof.

Abstract: The present technology generally relates to a microorganism displaying antigenic proteins of the SARS-CoV2 coronavirus on its surface, to methods of preparing same, to composition comprising such microorganism and to methods for treatment of SARS-CoV2 related infections in subjects.

Abstract: The present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

Abstract: Provided herein are a shingles vaccine composition including a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding varicella Zoster virus (VZV) glycoprotein E (gE)(which is soluble VZV gE or full-length VZV gE) and a method of inducing immune response against Shingles by administering an effective amount of the Shingles vaccine composition to a subject in need thereof.

Abstract: Methods are provided for promoting, reducing, or desensitizing various immune responses by delivery of sub-immunogenic doses of an allergen, alone or with other agents, or by delivery of antigens and adjuvants to a cutaneous microenvironment of a subject. Microneedle arrays can be used in connection with this delivery.

Abstract: Pharmaceutical composition comprising a conjugated peptide consisting of SEQ ID NO:1 to which several peptide epitopes are grafted covalently, kit comprising the elements for manufacturing this conjugated peptide, method of synthesis and use as vaccine.

Abstract: Provided herein are adjuvantation systems comprising fungal polysaccharides for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) and influenza (influenza A virus and influenza B virus) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus or influenza virus antigen.

Abstract: The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.

Abstract: Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.

Abstract: The present disclosure relates to methods of increasing the efficacy of adoptive cell therapy (ACT) and methods of treating cancer, wherein the methods include administering to a subject with cancer in need thereof a combination therapy comprising a therapeutically effective amount of an ACT (e.g., an immune cell comprising a modified T cell receptor (TCR) against a tumor-associated antigen (TAA), or a chimeric antigen receptor (CAR) against a TAA) and a therapeutically effective amount of a targeted immunocytokine (e.g., a fusion protein comprising an IL2 moiety and an immunoglobulin antigen-binding domain that binds to PD1). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and/or increased overall survival, as compared to a subject administered the ACT as monotherapy or the ACT in combination with a non-targeted immunocytokine.

Abstract: Provided herein are chimeric receptors, engineered cells and pharmaceutical compositions for enhancement of long-term clearance of protein aggregates in the central nervous system via phagocytosis or engulfment. Further provided herein are methods of treatment of subjects suffering from, or diagnosed with, a neurodegenerative disease by administering these receptors, modified cells, and/or pharmaceutical compositions. Administration of one or more, or a plurality of these modified cells, to a subject may provide treatment of a neurodegenerative disease such as Alzheimer's Disease (AD) or Parkinson's Disease (PD). Advantageously, the modified cells, pharmaceutical compositions, and methods of the present disclosure meet existing needs in the art by providing clearance of accumulations of protein aggregates in brain tissue in PD and AD pathologies.

Abstract: The present invention relates to the field of biomedicine, to an improved T cell receptor-costimulatory molecule chimera, in particular to a T cell receptor (TCR) or TCR complex comprising a costimulatory molecule, a T cell comprising the TCR or TCR complex, and the use thereof.

Abstract: Provided herein are immune cells and methods of use, wherein the immune cells include a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen binding domain that binds specifically to a first epitope; and an inhibitory chimeric antigen receptor (iCAR), wherein the iCAR comprises an extracellular antigen binding domain that binds specifically to a second epitope, wherein the immune cell is activated when the immune cells binds to the first epitope and does not bind to the second epitope; and wherein the immune cell is inactivated when the immune cell binds to the first and second epitopes.

Abstract: The present invention relates to a hydrogel composition comprising a chloroplast, a chloroplast transit peptide, alginate, and a pancreatic cell, and can supply oxygen to a cell or a tissue and control carbon dioxide and exhibits excellent preventive or therapeutic effects on diseases such as diabetes, etc., and thus may be utilized in the tissue engineering field such as organ transplant.

Abstract: A method for reducing hemolysis and microparticle formation during storage of pathogen reduced blood. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced hemolysis. Oxygen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles. Oxygen and pathogen reduced blood compositions comprising CPAD and riboflavin having reduced hemolysis. Oxygen and pathogen reduced blood compositions comprising SAGM and riboflavin having reduced microparticles.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases.

Abstract: The invention provides the use of an immunoadjuvant-based hydrogel in the preparing a sensitizing agent for surgical radiotherapy. The present invention also provides an immunoadjuvant-based hydrogel composition comprising sodium alginate, a tumor cell death marker aptamer, and a water-soluble immunoadjuvant with an extended sequence, wherein sodium alginate is covalently linked to the tumor cell death marker aptamer, and the sequence extended from the immunoadjuvant is partially complementary to the sequence of the tumor cell death marker aptamer. The immunoadjuvant-based hydrogel composition can undergo gelation in situ in the presence of calcium ions in the body, and realize the release of immune adjuvants in response to tumor cell death marker during tumor radiotherapy and the long-term intratumoral retention of immune adjuvant in the interval of radiotherapy, thus activating tumor-specific immune response for a long time during radiotherapy, and inhibiting the systemic metastasis of tumors.

Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.

Abstract: A natural absorbent excipient having multifunction developed by a twin-screw hot melt extrusion process is disclosed. The present invention discloses a natural excipient composition comprising: (a) natural coconut husk and/or coir pith powder from the husk of coconut, the fruit of Cocos nucifera; and (b) at least one polyol compound consisting of glycerol, sorbitol, polyethene glycol (PEG), propylene glycol (PG), and combinations thereof, wherein the weight ratio of (a) to (b) is in the range of 1:1-6:4.

Abstract: Methods for forming a sequence encoded oligomer includes oligomerizing first and second antibody-oligonucleotide conjugates through hybridization using at least one template oligo nucleotide. The first antibody-oligonucleotide conjugate comprises an oligonucleotide strand comprising a first sequence and a second sequence joined by an alkyne. The second antibody-oligonucleotide conjugate comprises an oligonucleotide strand comprising a third sequence and a fourth sequence joined by an alkyne.

Abstract: A poly ADP-ribose polymerase (PARP)-effector molecule conjugate comprising an automodified PARP having a plurality of poly ADP-ribose (ADPr) polymers on a surface of the automodified PARP, wherein the poly ADPr polymers comprise two or more 3?-azido NAD+ moieties, and the effector molecule is conjugated to at least one of the 3?-azido NAD+ moieties of the poly ADPr polymers while at least one of the 3?-azido NAD+ moieties remain unconjugated.

Abstract: This disclosure relates to the field of peptides, formulations, and methods of using the same, including but not limited to modified peptides derived from any of SEQ ID NOS. 1-29.

Abstract: A payload of drug conjugated to a targeting ligand specifically designed to deliver to exhausted CAR T cells to rejuvenate these CAR T cells is provided herein. The targeted CAR T cells are modified with a fusion receptor which can bind to the targeting ligand and internalize the conjugated payload of drug to execute its regulatory function to exhausted CAR T cell.

Abstract: A carrier-free nanoparticle based on the self-assembly of curcumin-erlotinib conjugate (EPC) that exhibits stronger cell killing, better anti-migration effects, and anti-invasion effects for pancreatic cancer cells than the combination of free curcumin and erlotinib.